Shares in nano-biotech newcomer Nexsen Ltd (ASX:NXN) jumped more than 37% by Tuesday afternoon, after the company’s $8 million initial public offering (IPO) found strong support in a market that has been warming to early-stage medtechs.
The stock opened at 20 cents and was trading at 27.5 cents by 2:35 pm AEDT — a confident first outing for a company pitching what it describes as lab-quality diagnostics in minutes.
A new listing with familiar ambitions
Nexsen’s technology traces back to RMIT University’s Sir Ian Potter Nanobiosensing Facility in Melbourne, where its biosensor platform was originally developed under nanotechnology specialist Professor Vipul Bansal. The company has licensed and refined the work into a modular, lateral-flow system that combines high-brightness nanoparticles and synthetic bioreceptors — known as aptamers — to detect disease targets with greater sensitivity than standard antibody-based tests.
It’s the same principle that underpinned COVID-19 rapid tests, but Nexsen’s platform aims for a much broader range of applications — from infectious disease and kidney function through to agricultural biosecurity.
The lead product is the GBS Rapid Sensor, designed to detect Group B Streptococcus in expectant mothers. The bacteria are common and usually harmless, but can be passed to newborns during labour, causing potentially serious infection. Current pathology methods can take up to 24 hours for a result; Nexsen’s device promises to deliver one in around 15 minutes, allowing clinicians to act while the patient is still in care.
While GBS is the immediate focus, Nexsen has signalled plans to extend the same biosensing platform into other areas of unmet need. Early projects include kidney-function tests for hospital and home settings, an at-home prostate-specific antigen screen, a veterinary diagnostic for bovine mastitis, and plant-pathogen detection for agricultural use.
The IPO story
The $8 million raise, managed by Alpine Capital, was pitched squarely at progressing the GBS program through clinical trials slated to begin in the December 2025 quarter, along with further platform development. RMIT University remains a shareholder, alongside several institutional investors.
Executive chair Reece O’Connell described the listing as “a bold and ambitious step” towards making accurate, affordable testing more accessible.
“Too often, critical health decisions are delayed or compromised because diagnostics rely on slow and costly laboratory systems,” he said in today’s announcement.
A brisk start — and the road ahead
Nexsen’s market debut fits the recent pattern of smaller ASX health-techs drawing strong first-day support as risk appetite returns to the small-cap end. The real work begins now: producing the clinical data to validate its lead test, navigating regulatory submissions, and scaling manufacture of devices and cartridges.
For investors, the company’s appeal lies in its platform flexibility — one reader system, many potential assays — and the clear clinical story anchoring its first use-case. The debut suggests investors are willing to give that story the benefit of the doubt, at least for now.